SCHEMBL2465797

SCHEMBL2465797

CC(Cl)NC(=O)N(N=O)C(C)Cl

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28697232 0.86 ALDH1A1 (0.35) ALDH1A1
SCHEMBL11035476 0.80
SCHEMBL11032565 0.76 ALDH1A1 (0.34) ALDH1A1
SCHEMBL10881978 0.75 MEN1 (0.30) ALDH1A1
SCHEMBL11034723 0.73 CAD (0.32) ALDH1A1
SCHEMBL6036958 0.73 MEN1 (0.40) ALDH1A1
SCHEMBL9710715 0.73
SCHEMBL11032591 0.72 MTOR (0.36) ALDH1A1
SCHEMBL10710775 0.72 MEN1 (0.35) ALDH1A1
SCHEMBL11036720 0.71 EPHX1 (0.39) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4777515-B2 2011-09-21 JP claimed
US-7498332-B2 Therapy for cerebral vasospasm DUKE UNIVERSITY (US) 2009-03-03 US claimed
EP-1124950-B1 Morpholino based p53 antisense oligonucleotide, and uses thereof AVI BIOPHARMA INC (US) 2006-07-12 EP claimed
WO-2005049811-A1 RADIOMINETIC METHOD OF PRODUCING A RODENT XENOGRAFT MODEL HAVING HUMANIZED MAMMARY FAT PAD WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2005-06-02 WO claimed
US-20020160001-A1 Therapy for cerebral vasospasm DUKE UNIVERSITY 2002-10-31 US claimed
JP-2002528464-A 2002-09-03 JP claimed
US-6365577-B1 p53 antisense agent and method AVI BIOPHARMA, INC. 2002-04-02 US claimed
EP-1124950-A2 p53 ANTISENSE AGENT AND METHOD Avi Biopharma, Inc. (US) 2001-08-22 EP claimed
WO-2000024885-A2 p53 MORPHOLINO-BASED ANTISENSE AVI BIOPHARMA, INC. (US) 2000-05-04 WO claimed
US-20180028677-A1 Peptides for Assisting Delivery Across the Blood Brain Barrier CHILDREN'S MEDICAL CENTER CORPORATION (US) 2018-02-01 US disclosed
US-9757470-B2 Peptides for assisting delivery across the blood brain barrier CHILDREN'S MEDICAL CENTER CORPORATION (US) 2017-09-12 US disclosed
US-20140294727-A1 PEPTIDES FOR ASSISTING DELIVERY ACROSS THE BLOOD BRAIN BARRIER CHILDREN'S MEDICAL CENTER CORPORATION (US) 2014-10-02 US disclosed
US-8748567-B2 Method for delivery across the blood brain barrier CHILDREN'S MEDICAL CENTER CORPORATION (US) 2014-06-10 US disclosed
US-7811587-B2 Botulinum toxin therapy for neuropsychiatric disorders ALLERGAN, INC. (US) 2010-10-12 US disclosed
US-20010053369-A1 Treating a movement disorder by intracranial administration of a neurotoxin, especially a botulinium toxin DONOVAN STEPHEN (US) 2001-12-20 US disclosed
WO-2001095924-A2 METHOD FOR TREATING A MOVEMENT DISORDER ALLERGAN, INC. (US) 2001-12-20 WO disclosed
US-6306403-B1 Method for treating parkinson's disease with a botulinum toxin ALLERGAN SALES, INC. 2001-10-23 US disclosed
EP-1124950-A2 p53 ANTISENSE AGENT AND METHOD Avi Biopharma, Inc. (US) 2001-08-22 EP disclosed
WO-2000024885-A2 p53 MORPHOLINO-BASED ANTISENSE AVI BIOPHARMA, INC. (US) 2000-05-04 WO disclosed
EP-0331505-A1 A method for purification of liposome composition Takeda Chemical Industries, Ltd. (JP) 1989-09-06 EP disclosed